NCT06923397 Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
| NCT ID | NCT06923397 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-06-05 |
| Primary Completion | 2026-11-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-06-05 with a primary completion date of 2026-11-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.
Eligibility Criteria
Inclusion Criteria: * Ability to understand and the willingness to sign informed consent prior to any study- related procedures. * Patients diagnosed with lymphoma. * Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis. * Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included. * Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise. * Have physician clearance to participate in exercise. * Speak English. * Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions. * Access to a phone that can receive text messages. Exclusion Criteria: * Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded. * Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention. * Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects. * Patients currently taking weight loss drugs. * Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study. * Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.
Contact & Investigator
Christina Dieli-Conwright, MD, PhD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06923397 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06923397 currently recruiting?
Yes, NCT06923397 is actively recruiting participants. Contact the research team at ChristinaM_Dieli-Conwright@dfci.harvard.edu for enrollment information.
Where is the NCT06923397 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06923397 clinical trial?
NCT06923397 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Christina Dieli-Conwright, MD, PhD at Dana-Farber Cancer Institute. The trial plans to enroll 24 participants.